Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99


External beam radiation therapy (EBRT) for asymptomatic bone metastases in patients with solid tumors reduces the risk of skeletal-related events (SREs).

Shulman RM, Meyer JE, Li T, Howell KJ.

Ann Palliat Med. 2018 Nov 6. pii: apm.2018.10.04. doi: 10.21037/apm.2018.10.04. [Epub ahead of print]


Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents.

Tanaka R, Yonemori K, Hirakawa A, Kinoshita F, Takahashi N, Hashimoto J, Kodaira M, Yamamoto H, Yunokawa M, Shimizu C, Fujimoto M, Fujiwara Y, Tamura K.

Oncologist. 2016 Apr;21(4):508-13. doi: 10.1634/theoncologist.2015-0377. Epub 2016 Mar 14.


Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.

Xie J, Namjoshi M, Wu EQ, Parikh K, Diener M, Yu AP, Guo A, Culver KW.

J Manag Care Pharm. 2011 Oct;17(8):621-43.


Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases.

Ulas A, Bilici A, Durnali A, Tokluoglu S, Akinci S, Silay K, Oksuzoglu B, Alkis N.

Tumour Biol. 2016 Jan;37(1):1131-40. doi: 10.1007/s13277-015-3907-z. Epub 2015 Aug 15.


Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting.

Trinkaus M, Simmons C, Myers J, Dranatisaris G, Clemons M.

Support Care Cancer. 2010 Feb;18(2):197-203. doi: 10.1007/s00520-009-0645-z. Epub 2009 May 8.


The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.

Delea T, Langer C, McKiernan J, Liss M, Edelsberg J, Brandman J, Sung J, Raut M, Oster G.

Oncology. 2004;67(5-6):390-6.


Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice.

Delea T, McKiernan J, Brandman J, Edelsberg J, Sung J, Raut M, Oster G.

J Support Oncol. 2006 Jul-Aug;4(7):341-7.


Cost of palliative external beam radiotherapy (EBRT) use for bone metastases secondary to prostate cancer.

Nickman NA, Ye X, Gaffney DK, Barney RB, Biskupiak JE, Okano GJ, Lee VC, Arellano J.

J Community Support Oncol. 2015 Mar;13(3):95-103. doi: 10.12788/jcso.0115.


Hospital visits among women with skeletal-related events secondary to breast cancer and bone metastases: a nationwide population-based cohort study in Denmark.

Svendsen ML, Gammelager H, Sværke C, Yong M, Chia VM, Christiansen CF, Fryzek JP.

Clin Epidemiol. 2013;5:97-103. doi: 10.2147/CLEP.S42325. Epub 2013 Mar 26.


Incidence, consequences and treatment of bone metastases in breast cancer patients-Experience from a single cancer centre.

Kuchuk I, Hutton B, Moretto P, Ng T, Addison CL, Clemons M.

J Bone Oncol. 2013 Oct 3;2(4):137-44. doi: 10.1016/j.jbo.2013.09.001. eCollection 2013 Dec.


Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer.

Klaassen Z, Howard LE, de Hoedt A, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ.

Cancer. 2017 May 1;123(9):1528-1535. doi: 10.1002/cncr.30505. Epub 2016 Dec 27.


Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer.

Delea TE, McKiernan J, Brandman J, Edelsberg J, Sung J, Raut M, Oster G.

J Thorac Oncol. 2006 Jul;1(6):571-6.


Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications.

Hirsh V, Tchekmedyian NS, Rosen LS, Zheng M, Hei YJ.

Clin Lung Cancer. 2004 Nov;6(3):170-4.


Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark.

Jensen AØ, Jacobsen JB, Nørgaard M, Yong M, Fryzek JP, Sørensen HT.

BMC Cancer. 2011 Jan 24;11:29. doi: 10.1186/1471-2407-11-29.


Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases.

von Moos R, Body JJ, Egerdie B, Stopeck A, Brown J, Fallowfield L, Patrick DL, Cleeland C, Damyanov D, Palazzo FS, Marx G, Zhou Y, Braun A, Balakumaran A, Qian Y.

Support Care Cancer. 2016 Mar;24(3):1327-37. doi: 10.1007/s00520-015-2908-1. Epub 2015 Sep 2.


Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?

Howard LE, De Hoedt AM, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Divers CH, Valderrama A, Freedland SJ.

Prostate Cancer Prostatic Dis. 2016 Dec;19(4):380-384. doi: 10.1038/pcan.2016.26. Epub 2016 Jul 5.


Opioid Use Among Metastatic Prostate Cancer Patients With Skeletal-related Events.

Yaldo A, Wen L, Ogbonnaya A, Valderrama A, Kish J, Eaddy M, Kreilick C, Tangirala K, Shields K.

Clin Ther. 2016 Aug;38(8):1880-9. doi: 10.1016/j.clinthera.2016.06.018. Epub 2016 Jul 29.


A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe.

Body JJ, von Moos R, Rider A, Hallworth P, Bhowmik D, Gatta F, Hechmati G, Qian Y.

J Bone Oncol. 2018 Dec 18;14:100212. doi: 10.1016/j.jbo.2018.100212. eCollection 2019 Feb.


Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre.

Murphy L, McCarthy J, McCrate F, Laing K, Powell E, Seal M, Edwards S.

Support Care Cancer. 2013 Jun;21(6):1557-60. doi: 10.1007/s00520-012-1694-2. Epub 2013 Jan 19.


Concurrent use of strontium-89 with external beam radiotherapy for multiple bone metastases: early experience.

Heianna J, Toita T, Endo W, Kasuya G, Ariga T, Hashimoto S, Maemoto H, Terui K, Miura N, Togashi A, Miyauchi T, Murayama S.

Ann Nucl Med. 2015 Dec;29(10):848-53. doi: 10.1007/s12149-015-1010-6. Epub 2015 Aug 13.


Supplemental Content

Support Center